Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28403441 | 0.98 | PNP (0.43) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL2352519 | 0.80 | PNP (0.43) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL28297130 | 0.78 | PNP (0.42) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL6275156 | 0.78 | PNP (0.42) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL133948 | 0.77 | PNP (0.41) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL28648090 | 0.77 | PNP (0.44) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL10998 | 0.77 | GDA (0.53) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL13007561 | 0.77 | PNP (0.41) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL8356642 | 0.77 | PNP (0.41) | PNPALDH1A1GDABLMMEN1 | |
| SCHEMBL9949248 | 0.77 | PNP (0.41) | PNPALDH1A1GDABLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-111315438-B | Transdermal drug delivery system | 爱肤柔生命科学公司 | 2022-09-27 | — | — | CN | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| CN-114814016-A | Method for rapidly detecting whether rhizoma atractylodis sinensis is doped in rhizoma atractylodis medicinal material | 湖北省药品监督检验研究院 | 2022-07-29 | — | — | CN | claimed |
| US-11324705-B2 | Transdermal drug delivery system | AVRO LIFE SCIENCES, INC. (CA) | 2022-05-10 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| EP-0644887-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID. | SMITHKLINE BEECHAM PLC (GB) | 1995-03-29 | — | — | EP | claimed |
| WO-1993025557-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1993-12-23 | — | — | WO | claimed |
| EP-0371844-B1 | USE OF ALPHA-TOCOPHEROL, BENZYL, XANTHINOL OR HEXYL NICOTINATE OR ALPHA TOCOPHEROL ACETATE IN A COSMETIC OR PHARMACEUTICAL SLIMMING COMPOSITION | L'OREAL (FR) | 1992-07-29 | — | — | EP | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| EP-0151987-B1 | MEANS FOR THE TREATMENT OF DISEASES OF THE VEINS AND THE ANAL REGION | Ismail, Roshdy, Dr. (DE) | 1991-05-29 | — | — | EP | claimed |
| EP-0371844-A2 | Use of alpha-tocopherol, benzyl, xanthinol or hexyl nicotinate or alpha tocopherol acetate in a cosmetic or pharmaceutical slimming composition | L'OREAL (FR) | 1990-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | PNP 2720/4885ALDH1A1 1917/4885GDA 4172/4885 |
| US-11324705-B2 | Transdermal drug delivery system | CUTA, AQP1, SLC26A4 | PNP 4575/4885ALDH1A1 1879/4885GDA 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.